Nyxoah Secures $15M EIB Loan Tranche, Raising $110M for U.S. Genio Launch
NYXH•Nyxoah has drawn down €13.8 million ($15 million) from the European Investment Bank’s second tranche of its loan facility after meeting drawdown criteria. Combined with its June underwritten public offering, the company has raised $110 million to fund Genio’s U.S. launch, R&D, and manufacturing scale-up.
1. EIB Tranche Drawdown
Nyxoah accessed the second tranche of its European Investment Bank loan by satisfying predefined criteria, resulting in €13.8 million ($15 million) in non-dilutive debt funding that bolsters its balance sheet without impacting existing share count.
2. June Capital Raise Total
In June 2026, Nyxoah combined this EIB financing with proceeds from an underwritten public equity offering, bringing total new capital raised to $110 million to support strategic growth initiatives.
3. Allocation of Proceeds
The company will deploy the funds primarily to accelerate the U.S. commercial launch of its Genio hypoglossal neurostimulation system, while also investing in ongoing research and development and scaling up manufacturing capacity.
